Innovent Biologics, Inc.（01801.HK）股价、图表、新闻与AI分析

Q: Innovent Biologics, Inc. 的 CEO 是谁？

Dr. De-Chao Yu 是 Innovent Biologics, Inc. 的 Executive Chairman of the Board，自 2011 加入公司。

Q: INNOVENT BIO 股票的价格表现如何？

INNOVENT BIO 的当前价格为 $83.2，在上个交易日 下降 了 2.23%。

Q: Innovent Biologics, Inc. 的主要业务主题或行业是什么？

Innovent Biologics, Inc. 属于 Biotechnology 行业，该板块是 Health Care

Q: Innovent Biologics, Inc. 的市值是多少？

Innovent Biologics, Inc. 的当前市值是 $143.1B

主页

股票

01801.HK

INNOVENT BIO (01801.HK)

Innovent Biologics, Inc.

HK$83.2

-2.23%

$-1.89

休市： Jan 20, 16:00:00 HKT

关键数据

前收盘价

$85.35

开盘价

$85.1

当日区间

$82.75 - $86.05

52周范围

$28.65 - $109.1

交易量

9.1M

平均成交量

14.6M

每股收益（TTM）

0.75

股息收益率

市值

$143.1B

什么是 INNOVENT BIO？

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 6,190 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly conducts its businesses within domestic and overseas markets.

功能特性

交易策略